Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (5289)	1/29/2007 9:33:26 PM
From: Ian@SI	Respond to of 7143

IJ, You trying to get me in trouble with Casaubon again? [See Valuation thread last week]

To: IRWIN JAMES FRANKEL who wrote (5289)	1/29/2007 9:55:41 PM
From: tnsaf	Read Replies (2) \| Respond to of 7143

It has appeared in the news, and a study was published. But, again, it is curing cancer in rats. Text below is from the University's web site: depmed.ualberta.ca Jason Frequently Asked Questions Updated January 23, 2007 Investigators at the University of Alberta have recently reported that a drug previously used in humans for the treatment of rare disorders of metabolism is also able to cause tumor regression in a number of human cancers growing in animals. This drug, dichloroacetate (DCA), appears to suppress the growth of cancer cells without affecting normal cells, suggesting that it might not have the dramatic side effects of standard chemotherapies. "CT-scan of rats with tumors (blue) growing in the flank" At this point, the University of Alberta, the Alberta Cancer Board and Capital Health do not condone or advise the use of dichloroacetate (DCA) in human beings for the treatment of cancer since no human beings have gone through clinical trials using DCA to treat cancer. However, the University of Alberta and the Alberta Cancer Board are committed to performing clinical trials in the immediate future in consultation with regulatory agencies such as Health Canada. We believe that because DCA has been used on human beings in Phase 1 and Phase 2 trials of metabolic diseases, the cancer clinical trials timeline for our research will be much shorter than usual. This website will be updated frequently to reflect progress in our efforts.